Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked
bleeding disorders. Replacement therapy has been the cornerstone of the management of …

Some non‐factor products that work by facilitating the coagulation pathway (emicizumab)
and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for …

Background Concizumab is an anti–tissue factor pathway inhibitor monoclonal antibody
designed to achieve hemostasis in all hemophilia types, with subcutaneous administration …

Hemophilia is a hereditary disease that remains incurable. Although innovative treatments
such as gene therapy or bispecific antibody therapy have been introduced, substantial …

Despite current therapies, there remains an unmet need for treatment for patients with
hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for …

For decades, the monogenetic bleeding disorders hemophilia A and B (coagulation factor
VIII and IX deficiency) have been treated with systemic protein replacement therapy. Now …

Mainstay haemophilia treatment, namely intravenous factor replacement, poses several
clinical challenges including frequent injections due to the short half-life of recombinant …

Progress in hemophilia therapy has been remarkable in the first 20 years of the third
millennium, but the innovation began with the description the fractionation of plasma in …

Marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway
inhibitor, demonstrated safety and efficacy in preventing bleeding episodes in patients with …

Tissue factor pathway inhibitor (TFPI) is an alternatively spliced anticoagulant protein that
primarily dampens the initiation phase of coagulation before thrombin is generated. As such …